Drug name - Venclexta
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8546399 | ABBVIE INC | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
Jun, 2031
(8 years from now) | |
| US10730873 | ABBVIE INC | Salts and crystalline forms of an apoptosis-inducing agent |
Nov, 2031
(9 years from now) | |
| US8722657 | ABBVIE INC | Salts and crystalline forms of an apoptosis-inducing agent |
Jan, 2032
(9 years from now) | |
| CN103328474A | ABBVIE INC | Salt And Crystalline Cell Apoptosis Inducing Agent |
Apr, 2018
(4 years ago) | |
| CN104906100A | ABBVIE INC | Cell Procedure Death Inducing Medicine Preparation For Treating Cancer And Immune And Autoimmune Disease |
Sep, 2019
(3 years ago) | |
| CN109897038A | ABBVIE INC | For Programmed Cell Death-Inducing Agent For The Treatment Of Cancer And Immune And Autoimmune Diseases |
May, 2030
(7 years from now) | |
| CN102448959B | ABBVIE INC | Cell Procedure Death Inducing Medicine Preparation For Treating Cancer And Immune And Autoimmune Disease |
May, 2030
(7 years from now) | |
| CN102448959A | ABBVIE INC | Apoptosis-Inducing Agents For Treatment Of Cancer And Immune And Autoimmune Diseases |
May, 2030
(7 years from now) | |
| CN104876927B | ABBVIE INC | A Programmed Cell Death Inducing Agent For The Treatment Of Cancer And Immune And Autoimmune Diseases |
May, 2030
(7 years from now) | |
| CN104876927A | ABBVIE INC | For The Treatment Of Cancer And Immune And Autoimmune Diseases Of Programmed Cell Death Inducing Agent |
May, 2030
(7 years from now) | |
| CN109897038B | ABBVIE INC | Cell Programmed Death-Inducing Agent For The Treatment Of Cancer And Immune And Autoimmune Diseases |
May, 2030
(7 years from now) | |
| CN103153993B | ABBVIE INC | Cell Procedure Disease Death Inducing Agent For Treating Cancer And Immune And Autoimmune |
Nov, 2030
(8 years from now) | |
| CN103153993A | ABBVIE INC | Cell Procedure Disease Death Inducing Agent For Treating Cancer And Immune And Autoimmune |
Nov, 2030
(8 years from now) | |
| EP2435432B1 | ABBVIE INC | Apoptosis-Inducing Agents For The Treatment Of Cancer And Immune And Autoimmune Diseases |
May, 2030
(7 years from now) | |
| EP2435432A2 | ABBVIE INC | Apoptosis-Inducing Agents For The Treatment Of Cancer And Immune And Autoimmune Diseases |
May, 2030
(7 years from now) | |
| EP2576546A1 | ABBVIE INC | Apoptosis-Inducing Agents For The Treatment Of Cancer And Immune And Autoimmune Diseases |
Nov, 2030
(8 years from now) | |
| EP2576546B1 | ABBVIE INC | Apoptosis-Inducing Agents For The Treatment Of Cancer And Immune And Autoimmune Diseases |
Nov, 2030
(8 years from now) | |
| EP2643322A1 | ABBVIE INC | Salts And Crystalline Forms Of An Apoptosis-Inducing Agent |
Nov, 2031
(9 years from now) | |
| EP2643322B1 | ABBVIE INC | Salts And Crystalline Forms Of An Apoptosis-Inducing Agent |
Nov, 2031
(9 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9174982 | ABBVIE INC | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
May, 2030
(7 years from now) | |
| US10993942 | ABBVIE INC | Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor |
Sep, 2033
(10 years from now) | |
| US9539251 | ABBVIE INC | Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor |
Sep, 2033
(10 years from now) | |
| US11110087 | ABBVIE INC | Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor |
Sep, 2033
(10 years from now) | |
Drugs and Companies using VENETOCLAX ingredient
Treatment: Treatment of adult patients with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll); treatment in combination with azacitidine or decitabine or low-dose cytarabine of newly-diagnosed acute myeloid leukemia (aml) in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy; treatment of patients with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll), with or without 17p deletion, who have received at least one prior therapy; treatment of adult patients with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll), with or without 17p deletion, who have received at least one prior therapy; Treatment of chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll) by orally administering venetoclax to an adult according to a dose ramp-up that includes a dose of 50 mg per day for 1 week followed by 100 mg per day for 1 week; Treatment of adult patients with chronic lymphocytic leukemia (cll) or small lymphocytic leukemia (sll) in combination with a ga101 antibody such as obinutuzumab for one or more dosing periods, wherein the cll or sll is a cd20-expressing cancer; Treatment of acute myeloid leukemia (aml) by orally administering venetoclax with azacitidine or decitabine or low-dose cytarabine in adults 75 years or older or having certain comorbidities according to a dose ramp-up including a 100 mg per day dose; treatment of chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll) by orally administering venetoclax to an adult according to a dose ramp-up including a 100 mg per day dose
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 10MG | TABLET;ORAL | Prescription |
| 50MG | TABLET;ORAL | Prescription |
| 100MG | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.